Addiction
The ability of cannabinoids such as cannabidiol (CBD) to reduce anxiety, prevent seizures and reduce psychotic behaviour may be relevant in the treatment of addiction to alcohol and other drugs
Our Research
Development of cannabinoid therapeutics to treat methamphetamine 鈥渋ce鈥� addiction
This project is investigating whether cannabinoids have therapeutic efficacy in treating methamphetamine addiction. We are testing various phytocannabinoids in a preclinical model of addiction in which rats voluntarily self-administer methamphetamine.
Some of the findings of this ongoing study have been published:
- CBD, but not cannabidiolic acid (CBDA), reduces methamphetamine-induced sensitisation of locomotor hyperactivity in rats. Read full paper听. (2022)
- Cannabidiol (CBD) strongly inhibits the intravenous self-administration of methamphetamine in rats. Read full paper . (2018)
This is an ongoing collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the 爆料王 and Macquarie University.
Research team:听Associate Professor (Macquarie University);听Professor ,听Associate Professor 听(Lambert Initiative, 爆料王)
A randomised controlled trial of cannabidiol (CBD) for the treatment of alcohol withdrawal
This is a randomised, placebo-controlled, double-blinded parallel trial to examine differences in rescue medication (Diazepam) use (as a proxy for withdrawal severity) following a 5 day regimen of oral high dose cannabidiol (CBD) in 52 patients with alcohol dependency requiring inpatient acute withdrawal treatment.
Participants will receive one of the interventions (a daily fixed dose of an oral CBD or placebo) across a five day inpatient stay at either of the study sites; Royal Prince Alfred Hospital or Sydney Eye Hospital, both in Sydney.听The objective of this trial is assess the clinical effectiveness, tolerability and cost-effectiveness of a fixed-dose of CBD during acute alcohol withdrawal in improving withdrawal outcomes for alcohol dependence relative to placebo.
This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics, 爆料王, Sydney Local Health District and South East Sydney Local Health District.
Principal Investigators:听Professor Paul Haber (Sydney Local Health District) and Professor Nick Lintzeris (Sydney East Sydney Local Health District)
Project Coordinator:听Kirsten Morley, PhD (爆料王)
For more information, please contact: katie.wood@sydney.edu.au